Summary.-The effects of Cisplatin on marrow haemopoietic progenitor cells, WBC and RBC were measured and compared in F1 (CBA x C57BL) female mice. Dose/ survival curves of Cisplatin for CFU-S, CFU-C and BFU-E were found to be simply exponential, indicating that the effect of the drug has no cell-cycle dependency. BFU-E also appeared significantly (P <0001) more sensitive to Cisplatin than CFU-S and CFU-C. After a single dose of 12 mg/kg of Cisplatin, WBC, MNC and CFU-E were seen to be markedly less reduced and to recover much earlier than CFU-C, and particularly BFU-E and CFU-S. Results suggest that the drug is more toxic for earlier haemopoietic progenitor cells than for the more mature cells, and that the latter are not reliable parameters for complete haemopoietic recovery in mice after treatment with this agent. In the animals treated, there was also a subsequent significant decrease of the RBC count, accompanied by a marked increase of the marrow CFU-E concentration. Possible underlying mechanisms (e.g. alterations of RBC after exposure to Cisplatin) were discussed.
CI SPLATIN
( cis-diamminedichloroplatinum II) has been shown to be an effective antineoplastic agent in experimental animals and in man (Prestayko et al., 1979) . In earlier studies, the major dose-limiting factor in the clinical use of this agent was reported to be the doserelated and cumulative renal toxicity (Krakoff, 1979; Talley et al., 1973) . The myelotoxicity of Cisplatin became increasingly evident after high doses of the drug were given with nephrotoxicity reduced by hydration and diuretics (Prestayko et al., 1979; Chary et al., 1977) . Recently, several investigators have reported severe myelosuppresion in patients treated with Cisplatin or chemotherapy combinations containing this agent (von Hoff et al., 1979; Kuzur & Greco, 1980) . The drug was found to induce not only leucocytopenia and thrombocytopenia, but also severe anaemia when given repeatedly, a phenomenon which is unusual in patient treated with combinations containing cytotoxic agents other than Cisplatin (Rossof et al., 1972; von Hoff et al., 1979; Kuzur & Greco, 1980) . The anaemia was considered to be secondary to changes in erythropoiesis, and in some cases to haemolysis (Kuzur & Greco, 1980; Rothmann & Weick, 1981; Getaz et al., 1980; Levi et al., 1981; van Nguyen & Jaffe, 1981) . However, the mechanisms responsible have not yet been thoroughly investigated. Moreover, few studies have been carried out to evaluate the effects of Cisplatin on haemopoiesis and particularly on haemopoietic stem cells. The drug has been shown to have a dose-related and cumulative toxicity for CFU-S and CFU-C in mice (Jenkins et al., 1981; Dumenil et al., in press) and to be more toxic to murine CFU-C than to human cells (Ogawa et al., 1975) .
The aim of the present study was to define the sensitivity of different haemopoietic stem cells to Cisplatin in mice, and to investigate the recovery of cells after a single dose of the agent equivalent in mice to doses usually given in man.
MATERIALS AND METHODS
Animals and drug admini8tration.-F1 (CBA x C57BL) female mice, 10-12 weeks of age and weighing 20-25 g, were used, both for Cisplatin treatment and as recipients for CFU-S assays. Cisplatin (Haereus, Hanau, F.R.G.) was appropriately dissolved in 0 5 ml sterile water and given i.p. Survival of cells was determined 24 h after injection of various drug doses, and recovery of cells after a single dose of 12 mg/kg of Cisplatin. The latter lies between the LD10 and the LD50 for mice (Penta et at., 1979) and using the conversion factor of Freireich et al. (1966) it is comparable to a single dose of 70 mg given to a human weighing 70 kg. Single-cell suspensions were prepared from flushed femoral marrow of 3 mice/group/point, and blood samples for individual WBC and RBC counts were obtained by severing the axillary vessels.
CFU-S, CFU-C, BFU-E and CFU-E assays.-CFU-S was assayed by the method of Till & McCulloch (1961) . Recipient mice, at least 10 mice/point/group, were exposed to 7-5 Gy total-body irradiation (X-ray machine, rate 1-43 Gy/min, focal distance 40 cm) before injection of 4 x 104 nucleated cells from the marrow (MNC). Macroscopic surface colonies in the spleens were counted 9 days later. CFU-C were assayed according to the method of Bradley & Metcalf (1966) as modified by Iscove (1972) . MNC 105 were cultured in 1 ml a-medium containing 0.8% methylcellulose, 20% horse serum and 20% mouse heartconditioned medium (Byrne et at., 1978) .
BFU-E and CFU-E were assayed by the method of Iscove & Sieber (1975) . MNC (2 x 105) were cultured in 1 ml Iscove's modified Dulbecco's medium containing 08% methylcellulose, 1% bovine serum albumin, 15% foetal calf serum, 15% horse serum, 10-4M 2-mercaptoethanol and sheep-plasma erythropoietin (2 U for BFU-E, 0-2 U for CFU-E, Connaught). All cultures were set up in triplicates and incubated at 37°C in a humified atmosphere with 5% CO2 in air.
CFU-C were scored on Day 7, BFU-E on Day 9 and CFU-E on Day 2 of incubation. BFU-E and CFU-E colonies were stained using an improved benzidine staining technique (Gallicchio & Murphy, 1979) .
Statistical analysis.-Linear regression was fitted according to the method ofleast squares. Significance of difference between the slopes of dose/survival curves was tested by comparing the regression coefficients using the t test. Recovery data were analysed on difference between the treated and control groups using both the t test and Mann-Whitney test.
RESULTS
The marrow nucleated cell count decreased progressively up to 75% of the control values with increasing doses of Cisplatin between 0'5 and 3 mg/kg. Thereafter, no further significant reduction was observed with higher doses. (Fig. 1) . BFU-E, in their nadir on Day 3 after treatment at addition, appeared to be significantly 65% of the control values; the cell number (P < 000 1) more sensitive to Cisplatin returned to normal by Day 8. than CFU-S and CFU-C.
The CFU-S number dropped rapidly to After a single dose of 12 mg/kg of 5% of the control value on Day 1 after Cisplatin, the WBC count showed a drug administration (Fig. 3) . Thereafter, decrease up to 53% of the control values the CFU-S compartment size increased during the first 3 days, followed by a progressively to reach subnormal levels by return to normal by Day 5 (Fig. 2) . The Day 15, and remained subnormal as long RBC count remained unchanged for the as the cells were studied. The CFU-C were first 2 days after drug application, but reduced up to 6% of the control value increased significantly (P < 0.05) above during the first 2 days after treatment; the normal levels by Days 3-5 and returned to cell concentration then started to rise, with normal by Day 8. During this period the a recovery of the cells being completed on animals frequently developed gastroenter-Day 15. itis and loss of weight. The increase of the The BFU-E had their nadir on Day 1 RBC count might therefore be, at least after treatment, where 0 85% ofthe control partially, due to dehydration. From Day value was achieved (Fig. 4) . Thereafter, 10, the RBC number decreased slowly but the cells began to recover, but their 399 132 .11 P. Drewinko et al., 1973) . The differential sensitivity of the cells to Cisplatin has to be considered valid only for the experimental conditions studied, since the slopes of dose/survival curves could change with variations in the interval between the drug administration and the assay of stem cells (van Putten et al., 1972) . Additionally, the different response of BFU-E and CFU-C to Cisplatin might be due to the different maturation stages of these cells and it could be that earlier congeners of CFU-C were similarly sensitive as are BFU-E.
--------------------
The more delayed recovery of CFU-S, BFU-E and CFU-C by comparison to MNC and WBC, suggest that the latter are not reliable parameters for complete haemopoietic recovery in mice after treatment with Cisplatin. If the same were true in humans, these indices, usually considered to be predictive for marrow toxicity of cytotoxic agents, could not be used for the evaluation of the true effect of Cisplatin on marrow function.
The recovery pattern of MNC and CFU-S after a single dose of 12 mg/kg of Cisplatin in mice is approximately comparable to that seen in the same animal species after exposure to 3-5 Gy wholebody irradiation (Valeriote et al., 1968; Guzman & Lajtha, 1970) . Additionally, the effects of Cisplatin on haemopoietic precursor cells resemble those of agents such as Busulphan and 1-bis(2-chloroethyl)-l-nitrosourea (BCNU), which have been shown to be more toxic to the earlier progenitor cells than to the more mature cells (Botnick et al., 1981) .
The toxicity of Cisplatin for CFU-S and CFU-C has been reported to be doserelated and cumulative (Jenkins et al., 1981; Dumenil et al., in press) . Considering this and our data, similar toxicities were possible for BFU-E, and these toxic effects could increase more rapidly with higher drug doses than that for CFU-S and particularly CFU-C. The question therefore arises whether the pronounced Cisplatin toxicity for BFU-E could be the cause of the anaemia induced by this agent. Such a preferential BFU-E depression has been reported from a single patient studied (Rothmann & Weick, 1981). However, the haemopoietic effects of Cisplatin might be different in mouse and man, as reported from in vitro studies on CFU-C (Ogawa et al., 1975) . Further investigations are therefore needed to clarify the sensitivity of different haemopoetic stem cells to Cisplatin in man, and to evaluate the recovery of cells after exposure to repeated doses.
The more prominent anaemia could also be due to different in vivo maturation times of erythroid and granulocytic progenitor cells. For example, it might be that if both cell populations were suppressed equally by Cisplatin, the smaller number of cells involved in erythropoiesis per unit time would eventually lead to a more pronounced anaemia than granulocytopenia. In Cisplatin-treated mice, however, the anaemia was accompanied by a marked increase of marrow CFU-E, indicating an appropriate response of the erythropoietic system, despite the protracted BFU-E recovery. The latter might therefore be a result of the need for an enhanced production of mature cells, and is compatible with the observation made in anaemic mice, in which an increase of CFU-E was associated with a decrease of BFU-E (Hara & Ogawa, 1977) . However, a delay in BFU-E recovery does not seem to be the cause of anaemia where normal or raised numbers of CFU-E are present. Although a high incidence of CFU-E has been shown to be not always reflected in effective production of mature cells (Testa, 1979; Pesch]e et al., 1980) , it also seems less likely that the reduced RBC count was a result of CFU-E maturation disturbances. Alternatively, the RBC number could be depressed by haemolysis. Haemolytic anaemia has been reported in patients treated repeatedly with Cisplatin (Getaz et al., 1980; Levi et al., 1981; van Nguyen & Jaffe, 1981) . The haemolysis was suggested as induced by antibodies reacting with Cisplatin-RBC-membrane complexes (Getaz et al., 1980) . Such an antibody-mediated haemolysis seems unlikely in our experiments, because of the single dose of the agent given, but other mechanisms (e.g. toxic effects of Cisplatin on RBC themselves) would also be able to induce a shortened cell survival, leading to anaemia. Therefore, appropriate studies concerning possible alterations of RBC after exposure to Cisplatin could be of value.
